Skip to search formSkip to main contentSkip to account menu

aclidinium

Known as: (3-Carbamoyl-3,3-diphenylpropyl)ethyldimethylammonium 
National Institutes of Health

Related topics

Related topics

3 relations
30 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza]aclidinium bromide

Narrower (1)

Tudorza

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
BACKGROUND Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long-acting beta… 
Highly Cited
2017
Highly Cited
2017
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of… 
2016
2016
The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
Background Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of… 
Review
2015
Review
2015
Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines
The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive… 
Review
2014
Review
2014
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
BACKGROUND Pharmacological therapy for chronic obstructive pulmonary disease (COPD) is aimed at relieving symptoms, improving… 
Highly Cited
2013
Highly Cited
2013
Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled…
Abstract Background: This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium… 
2013
2013
ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients
Background and ObjectivesAclidinium bromide is a long-acting muscarinic antagonist approved for the long-term maintenance… 
Highly Cited
2011
Highly Cited
2011
Aclidinium inhibits human lung fibroblast to myofibroblast transition
Background Fibroblast to myofibroblast transition is believed to contribute to airway remodelling in lung diseases such as asthma… 
Highly Cited
2010
Highly Cited
2010
Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways
Mucus hypersecretion and mucin MUC5AC overexpression are pathological features of chronic obstructive pulmonary disease (COPD… 
Review
2008
Review
2008
Novel long‐acting bronchodilators for COPD and asthma
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)